Home › Duchenne Muscular Dystrophy › NCT07766980
Evaluating VM100 Nutritional Supplement for Improving Quality of Life in Duchenne Muscular Dystrophy Patients
Who can join
Ages 6 and older · Men
Full eligibility criteria
Inclusion Criteria: * Diagnosis of DMD confirmed by genetic report * Age 8 years or older. * Stable glucocorticoid and/or other medication regimen for at least 3 months before enrollment and throughout study participation. Exclusion Criteria: * Unstable medical conditions or significant concomitant illness. * Secondary condition affecting muscle function or metabolism (e.g., myasthenia gravis, endocrine disorders, mitochondrial disease). * Participation in another investigational clinical trial within the previous 3 months.
About the study
This pilot study will investigate the potential efficacy of VM100, a nutritional supplement specifically formulated for patients with DMD, on quality of life and physical symptoms. Twenty patients (aged 8 an over) will be enrolled to undergo a 10-week placebo-controlled intervention with VM100. Outcomes will include validated questionnaires and qualitative interview to assess impact on mental, cognitive and mood related measures, as well as endurance and fatigue).
What is being tested
- VM100 Nutritional Supplement (dietary supplement)
Sponsor: University of Florida · Participants: 20 · Started: Jul 27, 2026
Contact the study team
- Tanja Taivassalo · Phone: (352) 294 - 8748
Official record on ClinicalTrials.gov — NCT07766980
Locations in the U.S.
| Florida | University of Florida, Gainesville |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.